세계의 전립선 비대증(BPH) 치료 시장은 2024년에 15억 3,000만 달러로 평가되었고, 예측 기간 중 연평균 복합 성장률(CAGR)은 8.75%로, 2030년에는 25억 1,000만 달러에 이를 것으로 예측됩니다.
세계 전립선 비대증(BPH) 치료제 시장은 고령화 인구 증가와 비뇨기과 건강에 대한 인식이 높아짐에 따라 꾸준히 성장하고 있습니다. 전립선 비대증(BPH)은 전립선의 비암성 비대증으로 불쾌한 배뇨 증상을 유발하고 삶의 질에 큰 영향을 미치는 질환입니다. 그 결과, 약물 치료부터 최소 침습적 시술 및 수술에 이르기까지 효과적인 치료 옵션에 대한 수요가 지역별로 확대되고 있습니다. 세계보건기구(WHO)의 예측에 따르면, 2050년까지 노인 인구의 약 80%가 중저소득 국가에 거주하게 될 것이라고 합니다. 또한, 80세 이상 고령자 수는 2020-2050년 사이 3배 증가하여 약 4억 2,600만 명에 달할 것으로 예측됩니다. 노화는 전립선 비대증(BPH)의 주요 위험인자이며, 그 유병률은 고령 남성에서 현저하게 증가합니다. 이에 따라 전 세계 노인 인구 증가는 효과적인 진단 및 관리 솔루션에 대한 수요 증가와 함께 향후 몇 년간 전립선비대증 치료제 시장의 큰 폭의 성장을 견인할 것으로 예측됩니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 15억 3,000만 달러 |
| 시장 규모 : 2030년 | 25억 1,000만 달러 |
| CAGR : 2025-2030년 | 8.75% |
| 급성장 부문 | α차단제 |
| 최대 시장 | 북미 |
의료기술의 발전으로 저침습적 치료법이 도입되어 회복 시간이 단축되고 치료 결과가 향상되어 더 많은 환자들이 적시에 치료를 받을 수 있게 되었습니다. 의약품 분야는 여전히 시장의 중요한 부분을 차지하고 있으며, α 차단제 및 5α 환원효소 억제제가 일반적으로 처방되고 있습니다. 한편, 레이저 치료 및 기타 에너지 기반 치료의 부상은 부작용이 적은 안전한 대안을 제공함으로써 수술의 전망을 재구성하고 있습니다. 신흥국의 의료 인프라의 성장도 진단과 치료에 대한 접근성을 높여 시장 성장을 더욱 촉진하고 있습니다. 라이프스타일의 변화, 의료비 증가, 비뇨기과 분야의 지속적인 연구 개발이 BPH 관리의 발전에 기여하고 있습니다. 환자의 편안함과 장기적인 치료 결과 개선에 초점을 맞춘 세계 BPH 치료 시장은 인지도와 기술 혁신이 진행됨에 따라 지속적으로 확대될 것으로 보입니다.
인구 고령화
고급 치료의 높은 비용
저침습적 치료로의 전환
Global Benign Prostate Hyperplasia (BPH) Treatment Market was valued at USD 1.53 billion in 2024 and is expected to reach USD 2.51 billion by 2030 with a CAGR of 8.75% during the forecast period. The global benign prostate hyperplasia (BPH) treatment market is experiencing steady growth, driven by the increasing prevalence of aging populations and rising awareness of urological health. BPH, a non-cancerous enlargement of the prostate gland, leads to uncomfortable urinary symptoms and significantly impacts quality of life. As a result, demand for effective treatment options-ranging from medication to minimally invasive procedures and surgery-is expanding across regions. According to World Health Organization (WHO) projections, by 2050, approximately 80% of the elderly population will live in low- and middle-income countries. Additionally, the number of individuals aged 80 and above is expected to triple between 2020 and 2050, reaching nearly 426 million. Age is the leading risk factor for benign prostatic hyperplasia (BPH), with its prevalence increasing significantly in older men. As a result, the growing global geriatric population is likely to drive substantial expansion in the BPH treatment market in the coming years, with heightened demand for effective diagnosis and management solutions.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 1.53 Billion |
| Market Size 2030 | USD 2.51 Billion |
| CAGR 2025-2030 | 8.75% |
| Fastest Growing Segment | Alpha Blockers |
| Largest Market | North America |
Advancements in medical technology have introduced less invasive treatment methods with shorter recovery times and improved outcomes, encouraging more patients to seek timely intervention. The pharmaceutical segment remains a key part of the market, with alpha-blockers and 5-alpha-reductase inhibitors being commonly prescribed. Meanwhile, the rise of laser therapies and other energy-based treatments is reshaping the surgical landscape by offering safer alternatives with reduced side effects. Growing healthcare infrastructure in emerging economies is also fostering access to diagnosis and treatment, further propelling market growth. The lifestyle changes, increased healthcare expenditure, and ongoing research and development in urology are contributing to the evolution of BPH management. With a focus on improving patient comfort and long-term results, the global BPH treatment market is poised to continue expanding as both awareness and technological innovation advance.
Key Market Drivers
Aging Population
The aging population is one of the most significant and influential drivers of the global benign prostate hyperplasia (BPH) treatment market. For instance, according to WHO 2025, global life expectancy at birth reached 73.3 years in 2024, rising by 8.4 years since 1995. The population aged 60 and older is expected to grow from 1.1 billion in 2023 to 1.4 billion by 2030, with the trend accelerating notably in developing regions. As men age, the likelihood of developing BPH increases substantially, making age a primary risk factor for the condition. BPH is characterized by the non-cancerous enlargement of the prostate gland, which commonly affects men over the age of 50. This physiological change occurs due to hormonal fluctuations, particularly the imbalance between testosterone and dihydrotestosterone (DHT), which promotes prostate cell growth. Over time, this leads to the gradual thickening and growth of the prostate, often resulting in urinary symptoms such as increased frequency, urgency, and incomplete bladder emptying.
Globally, improvements in healthcare, nutrition, and living standards have significantly extended life expectancy. This demographic shift means a larger proportion of the population is entering age brackets where BPH is more prevalent. Consequently, the demand for diagnostic, pharmaceutical, and surgical interventions is increasing. Healthcare systems, especially in developed countries, are seeing a growing burden of age-related conditions, with BPH being a leading urological issue among elderly men.
As people live longer and prioritize quality of life in older age, there is greater willingness to seek treatment for chronic but manageable conditions like BPH. The aging population is also more likely to be covered by healthcare insurance or public health systems, which further facilitates access to treatment. In emerging economies, increasing awareness among the elderly and improvements in medical infrastructure are similarly boosting diagnosis and treatment rates.
As this demographic trend continues, it is expected that the prevalence of BPH will rise, placing sustained demand on healthcare providers and driving innovation in less invasive, more effective treatment solutions. In this context, the aging population not only fuels market growth but also shapes the evolution of therapeutic strategies and healthcare delivery models for BPH.
Key Market Challenges
High Cost of Advanced Treatments
The high cost of advanced treatments poses a significant challenge to the growth and accessibility of the global benign prostate hyperplasia (BPH) treatment market. As medical technology evolves, newer treatment modalities such as laser therapies (e.g., HoLEP, GreenLight), water vapor therapy (Rezum), and prostatic urethral lift (UroLift) have emerged as preferred options due to their minimally invasive nature, shorter recovery times, and reduced side effects. However, these benefits come at a considerable financial cost. The equipment required for these procedures is often expensive, and so are the associated operational and maintenance costs, which are ultimately passed on to the patients or healthcare systems.
In many countries, especially those with limited healthcare funding or weak insurance infrastructure, the affordability of such advanced treatments becomes a major barrier. Patients in low- and middle-income regions may be forced to rely on older, more invasive procedures or pharmacological therapies, even when newer options would offer better outcomes. The private healthcare settings tend to dominate the availability of these innovations, making them inaccessible to individuals relying on public health services.
This economic disparity not only limits patient access but also discourages widespread adoption by healthcare providers due to the high initial investment. In addition, inconsistent or inadequate reimbursement policies in many regions further restrict the uptake of newer treatment modalities, particularly in outpatient settings. Without broader financial support or cost reduction strategies, the high cost of advanced BPH treatments remains a key obstacle to ensuring equitable access and scaling the market globally.
Key Market Trends
Shift Toward Minimally Invasive Procedure
The shift toward minimally invasive procedures is one of the most prominent trends shaping the global benign prostate hyperplasia (BPH) treatment market. Traditionally, BPH treatment involved surgical interventions such as transurethral resection of the prostate (TURP), which, while effective, often required prolonged hospital stays, significant recovery time, and a higher risk of complications such as bleeding and sexual dysfunction. In contrast, minimally invasive procedures offer a less traumatic alternative with quicker recovery, fewer complications, and a reduced risk of side effects, making them increasingly popular among both patients and healthcare providers.
Technologies like laser therapy (e.g., Holmium Laser Enucleation of the Prostate, HoLEP), prostatic urethral lift (UroLift), and water vapor therapy (Rezum) have gained traction due to their ability to treat BPH with precision and efficiency. These treatments are performed using advanced instruments that can target the enlarged prostate tissue without the need for large incisions, leading to shorter hospital stays, faster recovery times, and less post-operative pain. As a result, many patients are opting for these procedures over traditional surgery, valuing the minimal downtime and reduced risks.
This shift also aligns with a broader trend in healthcare toward procedures that maximize patient comfort and minimize disruption to daily life. The growing popularity of minimally invasive treatments is driving innovation in the field, encouraging the development of more effective, less invasive therapies. As awareness of these alternatives spreads, the market for minimally invasive BPH treatments is expected to expand, offering more choices for patients and enhancing the overall treatment landscape.
In this report, the Global Benign Prostate Hyperplasia (BPH) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Benign Prostate Hyperplasia (BPH) Treatment Market.
Global Benign Prostate Hyperplasia (BPH) Treatment Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report: